A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus in Adult Chinese Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase III
Latest Information Update: 07 Feb 2019
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 18 Dec 2018 Planned End Date changed from 29 Jan 2020 to 27 Apr 2020.
- 18 Dec 2018 Planned primary completion date changed from 29 Jan 2020 to 27 Apr 2020.
- 31 Aug 2018 Biomarkers information updated